About
Small Molecules, Diagnostics
Areas of Focus
Categories
DiagnosticsBiologics & BiopharmaceuticalVirus TechnologySmall Molecule PharmaceuticalJapan
Clinical Trials (8)
View allTotal Trials
8
As Lead Sponsor
3
As Collaborator
5
Total Enrollment
118
By Phase
PHASE2: 4PHASE1: 4
By Status
UNKNOWN: 4COMPLETED: 2RECRUITING: 1TERMINATED: 1
Clinical Trials Pipeline8 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT06340711Collaborator
Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
PHASE2Recruiting
27 participants
Started: Apr 25, 2024 · Completed: Apr 30, 2028
NCT04685499Collaborator
Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease
PHASE2Terminated
1 participants
Started: May 3, 2021 · Completed: Jun 3, 2022
NCT03921021Collaborator
Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
PHASE2Completed
17 participants
Started: May 9, 2019 · Completed: Jul 20, 2023
NCT03172819Collaborator
Special Combination of OBP-301 and Pembrolizumab
PHASE1Completed
22 participants
Started: Oct 1, 2017 · Completed: Apr 6, 2022
NCT03213054Lead Sponsor
A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer
PHASE1Unknown
12 participants
Started: Jul 7, 2017 · Completed: Jun 30, 2019
Locations (1)
Headquarters
Tokyo, Japan
Map
Loading map...